Adlai Nortye Ltd.
NASDAQ:ANLBiotechnology
-$0.11 today
- Market cap
- $503.20M
- Beta
- 0.99
- P/E (TTM)
- -3.0
- EPS (TTM)
- -$3.33
Volume 0.29M
Average 0.35M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Adlai Nortye Ltd.
NASDAQ:ANL
Intrinsic Alpha fair value
Locked
Current Price
$9.48
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | +37.0% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Forward estimates point to Revenue at +37.0% (5yr), giving you a quick read on expected growth from here.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Nuvation Bio Inc. NYSE:NUVB | $1.40B | $3.99 | Not rated | -12.8 | -18.75% |
Verastem, Inc. NASDAQ:VSTM | $1.03B | $8.18 | Not rated | -2.1 | -20.06% |
Corvus Pharmaceuticals, Inc. NASDAQ:CRVS | $897.52M | $10.64 | Not rated | -24.1 | +11.88% |
Compugen Ltd. NASDAQ:CGEN | $198.92M | $2.10 | Undervalued | 5.4 | +24.69% |
Foghorn Therapeutics Inc. NASDAQ:FHTX | $124.12M | $2.07 | Not rated | -3.8 | -63.55% |
Apollomics, Inc. NASDAQ:APLM | $51.54M | $17.68 | Not rated | -3.1 | -2.73% |
Continue the stock analysis
Jump to another research area for this company.